47.11
前日終値:
$47.21
開ける:
$47.13
24時間の取引高:
312.22K
Relative Volume:
0.50
時価総額:
$855.11M
収益:
$116.88M
当期純損益:
$-25.09M
株価収益率:
-336.50
EPS:
-0.14
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
-7.55%
1か月 パフォーマンス:
+66.00%
6か月 パフォーマンス:
+129.36%
1年 パフォーマンス:
+77.84%
Rigel Pharmaceuticals Stock (RIGL) Company Profile
名前
Rigel Pharmaceuticals
セクター
電話
650-624-1100
住所
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
RIGL
Rigel Pharmaceuticals
|
47.11 | 856.92M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-04-03 | 再開されました | Piper Sandler | Neutral |
| 2022-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-08 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | 開始されました | B. Riley Securities | Neutral |
| 2020-11-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-15 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-09-26 | 再開されました | JP Morgan | Overweight |
| 2019-03-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-08-27 | 開始されました | Citigroup | Buy |
| 2018-05-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-12-21 | 再開されました | Piper Jaffray | Overweight |
| 2017-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-11-06 | 再開されました | H.C. Wainwright | Buy |
| 2017-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | 繰り返されました | Piper Jaffray | Overweight |
| 2016-07-13 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-13 | 開始されました | Piper Jaffray | Overweight |
| 2016-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2013-04-08 | 繰り返されました | Stifel | Buy |
| 2012-11-29 | 開始されました | UBS | Neutral |
| 2012-11-06 | 繰り返されました | Oppenheimer | Outperform |
| 2012-03-26 | 開始されました | Canaccord Genuity | Hold |
| 2010-12-10 | ダウングレード | MP Advisors | Outperform → Market Perform |
すべてを表示
Rigel Pharmaceuticals (RIGL) 最新ニュース
Why pension funds invest in Rigel Pharmaceuticals Inc. (RI2) stock2025 Year in Review & Verified Stock Trade Ideas - Newser
Will Rigel Pharmaceuticals Inc. (RI2) stock enhance shareholder valueMarket Sentiment Report & AI Based Trade Execution Alerts - Newser
Is Rigel Pharmaceuticals Inc. (RI2) stock supported by free cash flowWeekly Investment Recap & AI Optimized Trading Strategy Guides - Newser
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock? - Yahoo Finance
Why Rigel Pharmaceuticals Inc. (RI2) stock could break out in 2025 - Newser
Will Rigel Pharmaceuticals Inc. (RI2) stock outperform small cap peers2025 Market Overview & Weekly High Potential Stock Alerts - Newser
(RIGL) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Is Rigel Pharmaceuticals Inc. (RI2) stock a top dividend aristocrat candidatePortfolio Performance Report & Long-Term Investment Growth Plans - Newser
Is Rigel Pharmaceuticals Inc. (RI2) stock a buy before new product rolloutWeekly Market Summary & Stock Market Timing Techniques - Newser
Can Rigel Pharmaceuticals Inc. (RI2) stock ride next bull market cycleTake Profit & Long-Term Capital Growth Strategies - Newser
Is Rigel Pharmaceuticals Inc. stock a buy for dividend growthMarket Performance Summary & Verified Technical Signals - Newser
What analysts say about Rigel Pharmaceuticals Inc RI2 stockVolume Analysis Techniques & Accelerated Financial Growth - earlytimes.in
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference - Eastern Progress
Is Rigel Pharmaceuticals Inc. stock near bottom after decline2025 Technical Overview & Low Risk Profit Maximizing Plans - moha.gov.vn
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue? - sharewise.com
Rigel Pharmaceuticals Inc RI2 Stock Analysis and ForecastSmall Cap Stock Opportunities & Discover Your Financial Freedom Formula - earlytimes.in
If EPS Growth Is Important To You, Rigel Pharmaceuticals (NASDAQ:RIGL) Presents An Opportunity - simplywall.st
Rigel Pharmaceuticals (RIGL) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Rigel Pharma: Q3 Earnings Showcase Robust Growth (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (Nasdaq: RIGL) plans Dec. 3 talk at Piper Sandler conference - Stock Titan
Rigel Pharmaceuticals: Behind The Huge Rally (NASDAQ:RIGL) - Seeking Alpha
Institutional Investors Control 85% of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) and Were Rewarded Last Week After Stock Increased 10% - 富途牛牛
Rigel Stock Surges on Upward Earnings Revisions - Ad-hoc-news.de
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 54% - 富途牛牛
How Recent Developments Are Rewriting the Story for Rigel Pharmaceuticals - Yahoo Finance
Rigel Pharmaceuticals, Inc.Common Stock (Nasdaq:RIGL) Stock Quote - Markets Financial Content
RIGLRigel Pharmaceuticals Stock Price and Quote - Finviz
How Rigel Pharmaceuticals Inc. (RI2) stock stacks up against competitorsJuly 2025 Analyst Calls & Safe Capital Allocation Plans - newser.com
How Rigel Pharmaceuticals Inc. (RI2) stock benefits from digital adoptionOptions Play & Daily Profit Focused Stock Screening - newser.com
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates - MSN
Rigel Pharmaceuticals’ olutasidenib shows efficacy in Phase 2 AML trial - MSN
How Rigel Pharmaceuticals Inc. (RI2) stock trades in high volatilityTrade Entry Summary & Breakout Confirmation Trade Signals - newser.com
Will Rigel Pharmaceuticals Inc. stock reach Wall Street targets2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
What insider trading reveals about Rigel Pharmaceuticals Inc. stock2025 Trade Ideas & Real-Time Stock Movement Alerts - newser.com
Measuring Rigel Pharmaceuticals Inc.’s beta against major indices2025 Performance Recap & Verified Trade Idea Suggestions - newser.com
Can machine learning forecast Rigel Pharmaceuticals Inc. recoveryJuly 2025 Summary & Weekly Stock Performance Updates - newser.com
Will Rigel Pharmaceuticals Inc. (RI2) stock sustain dividend payoutsEarnings Risk Report & Precise Trade Entry Recommendations - newser.com
Why Rigel Pharmaceuticals Inc. (RI2) stock benefits from AI revolutionWeekly Market Report & Fast Moving Stock Watchlists - newser.com
Applying big data sentiment scoring on Rigel Pharmaceuticals Inc.2025 Growth vs Value & Weekly Market Pulse Updates - newser.com
What is the fair value estimate for Rigel Pharmaceuticals Inc. (RI2) stock in 2025Portfolio Performance Summary & Free Fast Gain Swing Trade Alerts - newser.com
Why Rigel Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Macro Moves & Free Daily Entry Point Trade Alerts - newser.com
Will Rigel Pharmaceuticals Inc. (RI2) stock split increase liquidity2025 Macro Impact & Breakout Confirmation Trade Signals - newser.com
Will Rigel Pharmaceuticals Inc. stock attract ESG investorsPortfolio Risk Report & Intraday High Probability Alerts - newser.com
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Rigel Pharmaceuticals (RIGL) 財務データ
収益
当期純利益
現金流量
EPS
Rigel Pharmaceuticals (RIGL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
大文字化:
|
ボリューム (24 時間):